• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • [gtranslate]
  • Skip to main content

Chemical Market Reports

  • Home
  • All Reports
  • About Us
  • Contact Us

US Researchers Find Moderna’s Covid-19 Vaccine Reduces Hospitalization Risk By 95 Percent Than Pfizer, J&J

September 16, 2021 by Samuel Roan

The Delta variant of Covid-19 is having a devastating impact on America’s public health system. The rising cases have once again left the health authorities on their toes. The slow pace of vaccination in some parts has only added to the woes. President Joe Biden recently signed executive orders to step up efforts to vaccinate Americans who are yet to take even the first dose. He also signed punitive measures. Although America’s vaccination speed was highest in the world, the country didn’t manage to inoculate the entire population with two doses and provide a shield against the Delta variant. Vaccines that are being administered to Americans are Pfizer and Moderna. Both are two doses vaccines. The single-dose vaccine developed by Johnson & Johnson is also being given to people.

Vaccines are the most effective weapon to fight against Covid-19. However, the lower efficacy of vaccines against the Delta variant has come as a hindrance in the war. Scientists and doctors around the world are saying that a complete dose of vaccines can cut the threat of virus spread. Therefore, it becomes crucial to provide vaccines to the entire population. According to a new study, Moderna’s vaccine effectively works against Delta variant than other drugs. Indiana University researchers said that Moderna provides greater protection than vaccines developed by Pfizer and Johnson & Johnson. The study said that Moderna is 95 percent effective. It significantly cuts the risk of hospitalization.

Researchers said that the study involved adults above 18 years of age. They recommended that all eligible people should take vaccines. Vaccines reduce the severity in case of infection. They said that vaccination can ease the burden on the country’s hospitals and healthcare facilities. Researchers said that Pfizer’s vaccine is 80 percent effective at cutting the hospitalization risk due to the Delta variant. The vaccine developed by Johnson & Johnson works 60 percent against the variant. The study was done between June and August when the Delta variant was in the predominant phase. They found that unvaccinated people were required to visit hospitals around 5 to 7 times than those vaccinated group. The study added that vaccine effectiveness is lower in people above 75 years of age.

Related posts:

  1. SpaceX Falcon Heavy’s Next Launch Delayed By Several Months To ‘Accommodate Payload Readiness’
  2. Amazon Won’t Have To Pay USD 300 Million Tax Bill As It Wins Case Against EU Regulators
  3. Uber To Give UK Drivers Paid Vacation, Minimum Wage, Pension After Court Defeat
  4. Intel To Build Qualcomm Chips, Lays Roadmap To Expand Its New Foundry Business

Filed Under: Health

  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. Office No 8, 3rd Floor, Aston Plaza, Katraj - Ambegaon Road, Ambegaon BK, Pune, Maharashtra, India. Pin- 411046

Powered by Prudour Network

Copyrights © 2025 · Chemical Market Reports. All Rights Reserved.